Archives in cancer research最新文献_第4页

Disparity in Metabolic Conditions among Hispanic/Latina Women with Breast Cancer 西班牙裔/拉丁裔乳腺癌患者代谢状况的差异

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100187

D. Joh, G. Botrus, A. Dwivedi, L. Dongur, Z. Nahleh

{"title":"Disparity in Metabolic Conditions among Hispanic/Latina Women with Breast Cancer","authors":"D. Joh, G. Botrus, A. Dwivedi, L. Dongur, Z. Nahleh","doi":"10.21767/2254-6081.100187","DOIUrl":"https://doi.org/10.21767/2254-6081.100187","url":null,"abstract":"Background: Breast cancer is the most common cancer in Hispanic/Latina women. Common metabolic conditions prevalent in American Hispanics include diabetes mellitus, dyslipidemia, hypertension, and obesity and have been associated with poor overall survival. The association of such coexisting conditions with breast cancer risk, treatment and breast cancer characteristics in this population is largely understudied. In this study, we sought to explore the prevalence of one or combination of these comorbid conditions with breast cancer and possible association with breast cancer characteristics and subtypes in a predominantly Hispanic patient population. Methods: After IRB approval, we conducted a retrospective cross-sectional study of consecutive breast cancer patients treated in a University based tertiary medical center in the large border city of El Paso, TX. We evaluated the prevalence of 4 common metabolic conditions in a Hispanic patient population using the breast cancer center database of patients treated between 2005 and 2014. Adjusted association analyses were carried out using multiple Poisson regression analyses and results were presented with prevalence ratio (PR) and p-value.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68126791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II & III Breast Cancer 肿瘤浸润淋巴细胞和三级淋巴结构作为II期和III期乳腺癌新辅助化疗的预后和预测因素

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100178

L. Mohamed, A. Elsaka, Y. Zamzam, A. Elkady

{"title":"Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II & III Breast Cancer","authors":"L. Mohamed, A. Elsaka, Y. Zamzam, A. Elkady","doi":"10.21767/2254-6081.100178","DOIUrl":"https://doi.org/10.21767/2254-6081.100178","url":null,"abstract":"Purpose: Tumor-infiltrating lymphocytes (TILs) have a strong prognostic and predictive value in triple-negative breast cancer (TNBC) and HER2 enriched subtype but no other breast subtypes but no studies have evaluated tertiary lymphoid structure (TLS). Materials and Methods: Eighty patients with stage II and III breast cancer in Tanta oncology and pathology department with luminal A, B and her 2 enriched and TNBC diagnosed with core needle biopsy treated with neoadjuvant chemotherapy (4 AC followed by 12-week taxol + herceptin). TIL and TLS were evaluated histopathologically using hematoxylin and eosin–stained slides. The immune cell aggregates which were TLS positive showed the presence of CD20+ B lymphocytes within the follicles, with areas of CD3+, CD4+ T lymphocytes mainly in the periphery [T-cell zone] resembling the highly organized structures of secondary lymphoid organs. Results: TLS were detected in 53.7% of the tumors in whole breast groups, 83.7% in triple negative subgroup. Increased number of tumor infiltrating lymphocytes and tertiary lymphoid structure are associated with longer OS and DFS for TNBC and HER2-positive breast cancer. Conclusion: For predicting treatment response in patients with TNBC and HER2 enriched subtype, TILs and TLS may be prognostic and predictive marker triplenegative breast cancer (TNBC) and HER2 enriched subtype but no other breast subtypes.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Malignant Phyllodes Tumor in Ectopic Breast Tissue: A Case Report with a Literature Review 异位乳腺组织中恶性叶状瘤1例并文献复习

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100167

Imen Znagui, Slimani Olfa, Attia Moez, Ben Temim Riadh, Makhlouf Taher, M. Nabil, Attia Leila

{"title":"Malignant Phyllodes Tumor in Ectopic Breast Tissue: A Case Report with a Literature Review","authors":"Imen Znagui, Slimani Olfa, Attia Moez, Ben Temim Riadh, Makhlouf Taher, M. Nabil, Attia Leila","doi":"10.21767/2254-6081.100167","DOIUrl":"https://doi.org/10.21767/2254-6081.100167","url":null,"abstract":"Supernumerary breasts come from ectopic breast tissue which regression was incomplete. Typically, it is a single supernumerary gland, located in the axilla. Ectopic breast tissue is subject to the same pathologic events that occur in normally positioned breasts. Excision may be required for diagnosis, treatment of symptoms or cosmesis. We report a case report of a female patient aged 22 years, without medical history. She consulted for a left axillary swelling. Breast ultrasound showed: Voluminous mass of axillary tail with polylobed contours, Aspect evoking a phyllodes tumor. The patient had a wide excision. Anapath review concluded: Malignant phyllodes tumor in ectopic breast tissue and absence of residual tumor. Abdominal ultrasound and chest x-ray were normal. Adjuvant systemic treatment and radiotherapy were not delivered. Our patient is regularly followed: She doesn’t develop distant metastases or loco-regional relapse. Axillary ectopic breast tissue may provide a diagnostic challenge, as other benign and malignant lesions occur in this area. Malignant Phyllodes tumor in ectopic breast tissue is an extremely rare occurrence. Wide breast surgery is the mainstay of the treatment of non-metastatic malignant phyllodes tumors of the breast.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68124143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Radiation Therapy (RT) for Diffuse Intrinsic Pontine Glioma (DIPG) in Children 儿童弥漫性内生性脑桥胶质瘤(DIPG)的放射治疗

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100180

O. Sager, F. Dinçoğlan, S. Demiral, B. Uysal, H. Gamsız, F. Ozcan, E. Gundem, Y. Elcim, A. Ekmen, E. Onal, B. Dirican, M. Beyzadeoğlu

{"title":"Radiation Therapy (RT) for Diffuse Intrinsic Pontine Glioma (DIPG) in Children","authors":"O. Sager, F. Dinçoğlan, S. Demiral, B. Uysal, H. Gamsız, F. Ozcan, E. Gundem, Y. Elcim, A. Ekmen, E. Onal, B. Dirican, M. Beyzadeoğlu","doi":"10.21767/2254-6081.100180","DOIUrl":"https://doi.org/10.21767/2254-6081.100180","url":null,"abstract":"Tumours of the brainstem account for approximately 10% to 15% of all central nervous system (CNS) neoplasms in children, with diffuse intrinsic pontine glioma (DIPG) being the most common type. Affected patients with DIPG are mostly children at the age of 5 to 10-years-old. While brainstem gliomas may arise in other parts of the brainstem including the midbrain and medulla oblongata with a more favourable prognosis, pontine location is very frequent with a typically aggressive disease cause leading to a limited lifespan for the affected patients. Patients with DIPG may present with cranial nerve symptoms due to compression and dysfunction of nuclei and tracts located in the pons. A wide spectrum of symptoms may occur including impaired vision and diplopia, nausea and vomiting, headache, impaired alignment of the eyes, gait disturbances, dysarthria, facial asymmetry or weakness, impaired communication with altered levels of consciousness, changes in behaviour, impaired mobility, spasticity, weakness in legs and arms. Brainstem gliomas located at the pons with diffuse and extensive infiltration are typically not amenable for complete surgical resection. In this context, radiation therapy (RT) has traditionally been the mainstay of treatment for DIPG. Optimal radiation dose and fractionation and combined modality management with RT and chemotherapy has been the focus of extensive research over several decades. Herein, we assess the utility of RT for DIPG management in light of the literature.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100180","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Need For HBV Cure: Persistent RiskFor Subsequent New And Recurrent HCCEven After A Decade Of Successful Anti-HBVTherapy And Initial Tumor Ablation HBV治疗的需要:即使在10年成功的抗HBV治疗和最初的肿瘤消融后，后续新发和复发hcc2的持续风险

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100172

B. Shinn, C. Kistler, Christopher G. Roth, H. Hann

{"title":"Need For HBV Cure: Persistent RiskFor Subsequent New And Recurrent HCCEven After A Decade Of Successful Anti-HBVTherapy And Initial Tumor Ablation","authors":"B. Shinn, C. Kistler, Christopher G. Roth, H. Hann","doi":"10.21767/2254-6081.100172","DOIUrl":"https://doi.org/10.21767/2254-6081.100172","url":null,"abstract":"Since 1998 with the highly effective nucleos(t)ide analogues for Hepatitis B virus (HBV), we have witnessed successful viral suppression that has led to the delay or prevention of the development of hepatocellular carcinoma (HCC). Reduced incidence of HCC with anti-HBV treatment has been documented with lamivudine, entecavir and tenofovir. A number of investigators have observed that after the initial tumor was ablated, anti-HBV treatment could prevent or reduce the recurrent or subsequent new HCC. Nonetheless, as reported earlier, we are observing the persistent risk for HCC in patients in spite of successful viral suppression for over a decade with anti-HBV therapy. In this report, we present three cases who underwent initial tumor ablation and maintained negative HBV DNA with anti-HBV therapy and yet developed subsequent new or recurrent HCC at the intervals of 5,10,11 and 15 years. These persistent risks for new and recurrent HCC are attributed to the incomplete control of HBV due to the presence of cccDNA in the host’s hepatocytes. Current antiviral treatment can achieve a functional cure (suppression of HBV replication) while a complete cure of eliminating the cccDNA has not been possible. Therefore, even though HBV is not actively replicating, cccDNA remains in the nucleus of the hepatocytes and continues hepatocarcinogenic processes including HBV and host DNA integration. There is a need for HBV cure drugs.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100172","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis 萝卜硫素抑制肝癌细胞生长和血管生成

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100189

Shinya Sato, K. Moriya, Masanori Furukawa, Soichiro Saikawa, T. Namisaki, Mitsuteru Kitade, H. Kawaratani, K. Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, K. Seki, K. Kitagawa, Takemi Akahane, A. Mitoro, Yasushi Okura, H. Yoshiji, J. Yamao

{"title":"Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis","authors":"Shinya Sato, K. Moriya, Masanori Furukawa, Soichiro Saikawa, T. Namisaki, Mitsuteru Kitade, H. Kawaratani, K. Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, K. Seki, K. Kitagawa, Takemi Akahane, A. Mitoro, Yasushi Okura, H. Yoshiji, J. Yamao","doi":"10.21767/2254-6081.100189","DOIUrl":"https://doi.org/10.21767/2254-6081.100189","url":null,"abstract":"Sulforaphane (SFN) exhibits inhibitory effects in different types of cancers. However, its inhibitory effect on liver cancer remains unknown. This study aimed to determine the therapeutic potential of SFN for the treatment of liver cancer and explore the functional mechanisms underlying the inhibitory effects of SFN. Water-Soluble Tetrazolium salt (WST-1) assay was performed to assess the in vitro effect of SFN on cell proliferation in the human liver cancer cell lines, HepG2 and Huh-7. The mRNA levels of Nrf2 target genes and cell cycle-related genes were determined using quantitative RT-PCR. For assessing the inhibitory effect of SFN in vivo, we injected immortalized liver cancer cells into BALB/c nude mice as a xenograft model. SFN was orally administrated daily after tumor inoculation and continued for thirty-five days until their sacrifices. Nrf2 activation, induced by SFN, was confirmed by mRNA upregulation of HO-1, MRP2, and NQO1 in both the cell lines. Significant inhibition of liver cancer cell proliferation by SFN was shown in vitro in a dose-dependent manner by the downregulation of CCND1, CCNB1, CDK1 and CDK2. In in vivo studies, the administration of SFN significantly reduced the subcutaneous tumor burdens at the end of experiments by suppressing tumor cell proliferation, confirmed by Ki67 immunohistochemical analysis. The mRNA levels of CCND1, CCNB1, CDK1 and CDK2 were also decreased in these SFNtreated xenograft tumors. Moreover, CD34 immunostaining elucidated that the intratumoral neovascularization was markedly attenuated in the SFN-treated xenograft tumors. SFN exerts inhibitory effect on human liver cancer cells with antiangiogenic activity. The earlier version of this study was presented at the meeting of AASLD Liver Learning on Oct 2017.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68126458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide 非甲基化MGMT作为新诊断的多形性胶质母细胞瘤的预测因素，贝伐单抗联合伊立替康与替莫唑胺联合放疗和辅助替莫唑胺的比较

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100177

Lamiss Mohamed Ae, A. M. Elkady, Mamoun Abo Shosha, D. Mohamed

{"title":"Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide","authors":"Lamiss Mohamed Ae, A. M. Elkady, Mamoun Abo Shosha, D. Mohamed","doi":"10.21767/2254-6081.100177","DOIUrl":"https://doi.org/10.21767/2254-6081.100177","url":null,"abstract":"Background and Purpose: Temozolomide is the standard treatment for patients with newly diagnosed glioblastoma multiform that had methylated O6- methylguanine–DNA methyltransferase promotor, but it had a limited efficacy in non-methylated MGMT. Thus the aim of this study is to compare bevacizumab plus irinotecan versus standard temozolomide in newly diagnosed non methylated MGMT glioblastome multiforme. Patients and Methods: This study was carried out in oncology department, Tanta university hospital. Patients were randomized into two groups with ratio 2:1, group A received bevacizumab (BEV) (10 mg/kg every 2 weeks) during radiotherapy, followed by maintenance BEV (10 mg/kg every 2 weeks) plus irinotecan (IRI) (125 mg/m2 every 2 weeks) until progressive disease. Patients in the group B received 75 mg/m2 daily temozolomide (TMZ) during RT followed by adjuvant chemotherapy six cycles of TMZ (200 mg/m2 once daily for 5 days every 4 weeks). In recurrence in group B; patients could receive second-line BEV+IRI. The primary end point was the progression-free survival rate. Results: There was improvement in progression free survival, overall response and overall survival in favour of BEV+IRI versus TMZ. In univariate analyses for progression free survival, age, sex, performance status, extent of resection and line of treatment was statically significance while in multivariate they remained statistically significant. As regard overall survival all prognostic factors were significant in univariate analysis but only line of treatment was statically significant in multivariate analysis. Conclusion: BEV+IRI could be a good alternative to TMZ in nm MGMT newly diagnosed GBM but required larger studies.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"06 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Evaluation of Salivary Amylase and TotalProtein in Children with Acute LymphoblasticLeukemia in Basrah Pediatric OncologyCenter 巴士拉儿童肿瘤中心急性淋巴母细胞白血病患儿唾液淀粉酶和总蛋白的评价

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100188

J. Gh., Zainab Aj, Lamia Maln

{"title":"Evaluation of Salivary Amylase and TotalProtein in Children with Acute LymphoblasticLeukemia in Basrah Pediatric OncologyCenter","authors":"J. Gh., Zainab Aj, Lamia Maln","doi":"10.21767/2254-6081.100188","DOIUrl":"https://doi.org/10.21767/2254-6081.100188","url":null,"abstract":"Background: Saliva has found to be use as a diagnostic aid in an increasing number of clinical situations and in systemic disease that can affect salivary gland function and composition. Objective: To assess salivary amylase and total protein content in un- stimulated whole saliva in children with Acute Lymphoblastic Leukemia (ALL) at time of diagnosis and during induction phase of chemotherapy. Patients and methods: Thirty newly diagnosed children with acute lymphoblastic leukemia aged (1–14) years were recruited. Sixty healthy children matched for age and sex were regarded as control. Amylase and total protein were estimated in un-stimulated saliva from all subjects under study. Results: In children with ALL, the mean value of salivary amylase (817.05 ± 328.10 U/L) and total protein (10.20 ± 2.03 g/dl) were significantly higher before induction of chemotherapy than the controls (188.04 ± 124.7 U/L and 7.30 ± 0.82 g/dl, respectively) (p 0.05). Conclusion: Salivary amylase level significantly increases at time of diagnosis of acute lymphoblastic leukemia (ALL) and decreases during the induction phase of treatment with chemotherapy. So it can be regarded as diagnostic and prognostic indicator for acute lymphoblastic leukemia.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68126418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment IMRT与VMAT方案治疗晚期非小细胞肺癌的比较

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100185

Choi Jh

引用次数: 7

Flavonoids in Triple Negative Breast Cancer: Chemopreventive Phytonutrients 三阴性乳腺癌中的类黄酮:化学预防植物营养素

Archives in cancer research Pub Date : 2018-01-01 DOI: 10.21767/2254-6081.100170

D. Kashyap, H. Tuli

{"title":"Flavonoids in Triple Negative Breast Cancer: Chemopreventive Phytonutrients","authors":"D. Kashyap, H. Tuli","doi":"10.21767/2254-6081.100170","DOIUrl":"https://doi.org/10.21767/2254-6081.100170","url":null,"abstract":"Flavonoids are phytochemicals that found in a variety of fruits and vegetables and known to possess anti-oxidant, antiinflammatory and anti-cancer properties [1,2]. It has been considered that flavonoids rich diet intake has promising role in human cancer prevention including breast cancer [3]. These phytonutrients have been traditionally used in Chinese and Ayurvedic medicine and are found to be associated with lower risk of breast cancer [4,5]. According to epidemiological studies, breast cancer is the most common malignancies in women around the globe [6]. Breast cancer has heterogeneous nature with each of its subtype shown distinct morphological and clinical behavior [7]. Several factors including genetic, epigenetic and transcriptomic alterations are proved to be responsible for this diverse nature of breast cancer [8]. Among other subtypes triple negative breast cancer (TNBC) is highly aggressive form of breast cancer [9]. Statically TNBC alone comprises of 10%-17% of all breast carcinomas with incidence rate of 6%-28% of breast cancer [10]. Although, TNBC accounts for small proportion of all breast cancers, but has high mortality rate due to its aggressive nature. TNBC is characterized by the absence of estrogen receptors (ERs), progesterone receptors (PRs) and human epidermal growth factor receptor 2 (HER2) with normal breast tissue–like, and basal-like phenotype [10]. Lack of ERs, PRs and HER2 in TNBC makes it more difficult to treat [11]. Currently used hormonal or targeted therapies are only effective against those tumors that has either overexpressed receptors or transcriptional factors. Since neither receptors nor HER2 overexpression is occurred in TNBC therefore the therapies are found to be ineffective [11]. Interestingly, several in-vitro experiments determined the risk reducing effect of flavonoids in TNBC and suggesting them as a promising therapy.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100170","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68124292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5